CA9 and breast cancer: On the other hand, based on a more comprehensive and clear regulatory network of CAXIIis, more chances could be gained by expanding their application in different combination therapies with multiple targets for treating cancer, as shown in a preclinical study that combined CAIX and CAXII dual inhibition with immune checkpoint blockade resulting in improved efficacy of immune therapy in melanoma and breast cancer (53).